Abbott Labs is jumping on the transcatheter mitral valve replacement (TMVR) bandwagon with an agreement to buy out the rest of Tendyne Holdings and an option to Cephea Valve Technologies, both announced July 30.
Abbott will buy the remaining equity of Tendyne that it does not already own for $225m upfront, giving a total transaction value of $250m and has agreed
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?